The announcement of a $125 million common stock offering by Editas Medicine may lead to a short-term negative impact on the stock price. This is because the offering dilutes the value of existing shares, and the market may react negatively to the dilution. However, the funds raised will be used for research and development, which could potentially lead to long-term growth for the company.